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Abstract 
Background: Despite advances to targeted leishmanicidal chemotherapy, defies around severe toxicity, recent 
emergence of resistant variants and absence of rational vaccine still persist. This necessitates search and/or progres‑
sive validation of accessible medicinal remedies including plant based. The study examined both in vivo and in vitro 
response of L. major infection to combined therapy of Ricinus communis and Azadirachta indica extracts in BALB/c 
mice as the mouse model. A comparative study design was applied.
Results: BALB/c mice, treated with combination therapy resulted in significantly (p < 0.05) larger reduction of lesion 
than those treated with monotherapies. The spleno‑somatic index was found to be significantly low with combina‑
tion therapy than monotherapies. Antiparasitic effect of A. indica and R. communis on amastigote with a 50 % inhibi‑
tory concentration (IC50) was of 11.5 and 16.5 µg mL
−1 respectively while combination therapy gave 9.0 µg ml−1 
compared to the standard drugs, Pentostam and amphotericin B which had an IC50 of 6.5 and 4.5 µg ml
−1 respec‑
tively. Optimal efficacy of A. indica and R. communis was 72 and 59.5 % respectively, combination therapy gave 88 %, 
while Pentostam and amphotericin B had 98 and 92 % respectively against amastigotes. Against promastigotes A. 
indica and R. Communis gave an IC50 of 10.1, 25.5 µg mL
−1 respectively, while combination, 12.2 µg mL−1 against 
4.1 and 5.0 µg ml−1 for Pentostam and amphotericin B respectively. The optimal efficacy of the compounds against 
promastigotes was 78.0, 61.5 and 91.2 % (A. indica, R. communis and A. indica + R. communis respectively) against 96.5 
and 98 % for Pentostam and amphotericin B respectively. The concentrations at optimal efficacy were significantly 
different (p < 0.05) among the test compounds. An evaluation of the IC50 values of the combination therapies clearly 
reveals synergistic effects.
Conclusion: Combination therapy of A. indica and R. communis had best antileishmanial activity than the monother‑
apies. The active ingredients of both R. communis and A. indica need to be fractionated, and studied further for activity 
against Leishmania parasites.
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Background
In many tropical and subtropical developing countries, 
protozoan parasites are amongst the most common 
infectious agents and have serious consequences for 
socio-economic development [1, 2]. The World Health 
Organization (WHO) considers leishmaniasis to be one 
of the most serious parasitic diseases and the World 
Health Assembly has advocated a concertation for its 
control [3]. Due to species differences in tissue tropism, 
virulence and their interaction with the host’s immune 
system, infection by leishmaniasis can result in a variety 
of clinical manifestations ranging from single self-heal-
ing ulcers in cutaneous forms to life threatening visceral 
infections [4, 5]. The pentavalent antimonials sodium sti-
bogluconate and meglumine antimoniate alongside their 
generics have been the first-line treatment for leishmani-
ases in many areas for decades [6–8]. Albeit, antimoni-
als are considered to be toxic with frequent, sometimes 
life-threatening, adverse side effects. Patients under the 
age of 2 or aged ≥45 with signs of advanced disease and/
or severe malnutrition are at higher risk of death during 
therapy owing to drug toxicity, slowness of drug action, 
infection complications or a combination of these factors 
[9–11]. Although there is still a need for more research 
and development (R&D) to improve the drug pipeline for 
leishmaniasis [12], some alternatives have become avail-
able in recent years. The most pressing research needs for 
leishmaniasis control are the search for alternative and 
cost effective drugs for oral, parenteral or topical admin-
istration in shorter treatment cycles, and identification of 
mechanisms to facilitate access to existing control meas-
ures, including health-sector reform in some developing 
countries. These will help mitigate the neglected tropical 
disease (NTDs) associated chronic vicious cycle of pov-
erty in sub-Saharan Africa and other contexts with high 
prevalence.
The castor oil plant, Ricinus communis is a species of 
flowering plant in the spurge family, Euphorbiaceae. It 
belongs to a monotypic genus, Ricinus, and sub-tribe, 
Ricininae. Alcoholic extract of the leaf has been shown 
to be hepatoprotective in rats [13]. Methanolic extracts 
of the leaves of R. communis have shown antimicrobial 
properties [14]. The pericarp of castor bean showed cen-
tral nervous system effects in mice at low doses. Anti-
histamine and anti-inflammatory properties have been 
found in ethanolic extract of R. communis root bark [15]. 
The neem tree, Azadirachta indica, A. Juss (Meliaceae) 
is an Indian tree that has many useful compounds that 
act as insecticide. It has also been documented to have 
anti-leishmanial effect on L. donovani [16]. However, lit-
tle information is available on efficacy of combination 
therapy of A. indica and R. communis.
Considering conventional targeted leishmanicidal 
chemotherapy options are out of reach for most rural 
communities in developing countries, alternatives are 
bound to be sort or incorporated in rational management 
of the complication. Evidently, many of these populations 
and individually held knowledge by the traditional health 
practitioners (THP) know a lot about medicinal flora 
that can cure a diversity of diseases while combination of 
medicinal remedies by the herbalists/self-prescription is 
now a common occurrence [17–20], but due to a number 
of protocols required, their effective use remain specula-
tive. There are limited studies available interrogating the 
anti-parasite properties on synergistic, antagonistic or 
toxicity effect of combined medicinal therapies in vari-
ous medical conditions. Furthermore, efficacy of plant 
extracts is known to be affected by among other things; 
location, amount of active compounds in the plants, 
extraction procedure and species of organism under 
study; which makes it very difficult to generalize the anti-
parasitic/pathogenic properties of many plant species. In 
light of this, especially in the tropical regions where there 
are large forested land under these plants, the aim of this 
study was to assess response of Leishmania major to 




The in  vivo and in  vitro studies were carried out using 
a comparative study design. The efficacy and toxicity of 
samples were compared with those of Pentostam (Glax-
oSmithKline, UK) and amphotericin B [Fungizone™, 
X-Gen Pharmaceuticals (US)]. In vivo studies were fur-
ther subjected to a complete randomized block design. 
The results were compared to determine the efficacy of 
the test samples against the known standard drugs for 
treating leishmaniasis.
Anti‑leishmanial plants and extracts
The plant extracts were obtained from the A. indica 
and R. communis. Leaves of A. indica and R. communis 
were collected from Kakamega forest Western region of 
Kenya with the assistance of a plant taxonomist and their 
voucher specimens were deposited at the East African 
Herbarium, National Museums of Kenya, Nairobi, Kenya 
(Ricinus communis TFm13 and Azadirachta indica 
TFm23). The plant extracts were processed according to 
the method of Kigondu et al. [21]. The plant parts were 
chopped into small pieces; air dried at room temperature 
(25 °C) for 14 days and pulverized using a laboratory mill 
(Christy & Norris Ltd., Chelmsford, England). 1  kg of 
each powder was soaked in absolute methanol for 3 days 
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to extract compounds. The extract was filtered, dried 
with Na2SO4 and the solvent removed under vacuum in 
a rotary evaporator at 30–35 °C. For aqueous extraction, 
100 g of ground material in 600 ml of water was placed in 
a water bath and maintained at 60 °C for 2 h. This filtrate 
was freeze dried (using a Freeze Dryer, Edwards freeze 
dryer Modulyo), weighed and stored at −20  °C until 
required for use. DMSO was used in all the drug for-
mulations because it has been reported to increase drug 
penetration [22]. These methanolic extracts were used 
for anti-leishmanial testing. The plant yields for A. indica 
and R. communis were 15–18 % w/w and 10–15 % w/w of 
plant leaves respectively.
Mice and parasites
Female 8 week old BALB/c mice weighing 20 ± 2 g were 
used in the experiment. The animals were obtained 
from Kenya Medical Research Institute (KEMRI) ani-
mal breeding facility, Nairobi-Kenya. The animals were 
moved into the experimental room for acclimatization 
one week before the start of the experiments. The mice 
were housed in 15  cm  ×  21  cm  ×  29  cm transparent 
plastic cages. They were fed with pellets (Mice pellets 
UNGA® feeds) and water ad libitum.
Leishmania major (strain IDUB/KE/83  =  NLB-144) 
which was originally isolated in 1983 from a female P. 
duboscqi collected near Marigat, Baringo County Kenya 
was used [23]. The L. major strain was maintained by 
serial passage in BALB/c mice to maintain virulence. 
An aspirate isolate from the footpad of infected BALB/c 
mouse was cultivated in Schneider’s Drosophila insect 
medium (Sigma, Saint Louis, USA), supplemented with 
20 % heat inactivated foetal bovine serum (FBS) (Cultilab, 
Campinas, SP, Brazil), 500  µg/ml penicillin, 500  µg/ml 
streptomycin and 250 µg/ml 5-fluorocytosine arabinoside 
(all from Gibco, Grand Island, NY, USA) [24, 25]. Pro-
mastigotes were incubated at 25  °C grown to stationary 
phase to generate infective metacyclic forms at 6th day of 
culture. Promastigotes in the medium were counted with 
a hemocytometer (Improved Double Neubauer) (Phar-
macia-GE Healthcare, Uppsala, Sweden) with a Nikon 
optiphot optical microscope at 40× magnification.
In vitro studies
Cytotoxicity assay
In vitro cytotoxicity assay was carried out following a 
modified rapid colorimetric assay as previously described 
by Mosmann [26]. Vero cells were cultured and main-
tained in Eagle’s Minimum Essential Medium (MEM) 
supplemented with 10  % FBS. The cells were cultured 
at 37  °C in 5  % CO2 for 24  h, harvested by trypsiniza-
tion, pooled in a 50  ml vial and 100  µl cell suspension 
(1  ×  106  cells/ml) put into 2 wells of rows A-H in a 
96-well micro titer Nunc-Immuno™ (MaxiSorp™ Sur-
face) plate, the medium aspirated off and 150  µl of the 
highest concentration of the A. indica and R. communis 
added into the same row and serial dilution. The con-
trols used were cells with no extract and medium alone. 
MTT (3-4, 5-dimethgylthiaol-2-yl-2, 5-diphenyltetrazo-
lium bromide) reagent (10 µl) was added into each well 
and the cells incubated for 4 h. After which, the medium 
together with MTT were aspirated off. Dimethylsulfox-
ide (DMSO) (100  µl) was added and the plates shaken 
for 5 min. The absorbance was measured for each well at 
562 nm using a micro-titre plate reader [27].
Minimum inhibitory concentration (MIC) 
and anti‑promastigotes assay
Leishmania major promastigotes (106  parasites/ml) was 
incubated at 26 °C for 120 h in fresh media (brain heart 
infusion medium), supplemented with 10  % FBS in the 
absence or presence of serial concentrations (100, 50, 25, 
12.5, 6.25 and 3.125  µg/ml) of the extracts. Cell growth 
was determined daily by assessment of visible turbidity. 
The MIC was considered as the lowest concentration of 
each substance used that inhibited more than 99 % of L. 
major growth in vitro.
Promastigotes were incubated in 24-well plates in the 
presence of serial concentrations of the extracts for 120 h. 
Aliquots of parasites were then transferred to 96-well 
Nunc-Immuno™ (MaxiSorp™ Surface) microtiter plate, 
incubated at 27  °C in 5  % CO2 for 24  h, then 100  μl of 
highest concentration of the extract was added and seri-
ally diluted, then incubated further at 27 °C for 48 h. The 
controls used were promastigotes with no extract and 
medium alone. MTT reagent (10 μl) was added and incu-
bated for 4 h, then the medium together with MTT was 
aspirated off; DMSO (100  μl) was added and the plates 
were shaken gently for 5 min. The absorbance was meas-
ured for each well at 562  nm using a micro-titer plate 
reader [26].
Macrophage cultures for anti‑amastigote assay 
and determination of nitric oxide
Four days after intraperitoneal injection of female 
BALB/c mice (8–12 week old; Kenya Medical Research 
Institute (KEMRI) animal breeding facility, Nairobi-
Kenya) with 4  % Brewer’s thioglycolate broth (Difco, 
Inc., Detroit, MI), peritoneal macrophages were har-
vested with Phosphate-buffered saline (PBS) and pro-
cessed as described [28, 29]. The derived macrophages 
were infected with L. major stationary phase promas-
tigotes at a 6:1 parasite/macrophage ratio. Uninfected 
macrophages were used as negative controls. Infected 
macrophages were incubated at 37 °C in 5 % CO2 for 4 h. 
After incubation, the remaining extracellular parasites 
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were removed by gentle washing and the cultures incu-
bated in RPMI (JRH Biosciences, Lenexa, KS) for 24 
h. Subsequently, treatment of infected macrophages 
with the R. communis and A. indica was done as ear-
lier described [30, 31].The medium replenishment was 
for 3 days (24, 48 and 72 h time points). Pentostam and 
amphotericin B were used as a positive control drugs for 
comparison of parasite inhibition. On day four, the wells 
were washed twice with normal saline and the reaction 
was stopped by adding stop solution, then incubated 
for 2 h, washed twice with normal saline and fixed with 
methanol then stained with Giemsa stain. The infec-
tion levels were determined by counting the percentage 
of infected cells and the number of amastigotes per 100 
macrophages [30]. This analysis was performed by two 
independent observers who were blinded to the experi-
mental conditions. After each time point, supernatants 
were harvested and stored at −70 °C for analysis of nitric 
oxide (NO) production. Nitrite (NO2−) accumulation in 
the cell culture supernatants was used as an indicator of 
NO production and was determined by a standard Griess 
reaction [28, 29, 32].
In vivo; experimental infections setup, treatment, lesion 
measurement and parasite burden
For in vivo settings, the sample size was calculated using 
the resource equation method [33]. 48 BALB/c mice 
were inoculated with 1 × 106 stationary phase L. major 
promastigotes in 50  µl phosphate buffered saline into 
the Left Hind Footpad (LHFP) using a 29 gauge needle 
and left for 4  weeks incubation period [34]. The inocu-
lated mice were then randomly assigned into 6 groups of 
8 mice in each. Group 1 treated with A. indica extracts, 
group 2 with R. communis, group 3 with combination of 
A. indica (10 ml/kg) and R. communis (15 ml/kg), group 4 
with sterile PBS, group 5 Pentostam and group 6 ampho-
tericin B; treatment commenced on the 5th week post 
infection (day 29), for 28  days [34–36]. All treatments 
were done intraperitoneally.
A total of four mice per group were sampled at week 10 
for analysis of L. major parasite loads. Lesion size, which 
was defined as the difference in thickness between the 
infected footpad and the non-infected contralateral Foot-
pad, was monitored weekly by measurement using a Star-
ret dial caliper (Mitutoyo, Suzano, SP, and Brazil) [37, 38]. 
The weight of the mice was also monitored on a weekly 
basis. The spleen were removed and weighed and changes 
post-infection and chemotherapy were determined 
based on spleno-somatic indices as previously described 
[39]. Splenic L. major burdens were determined from 
Giemsa-stained impression smears and expressed as 
Leishman-Donovan units (the number of amastigotes per 
1000 host nuclei, multiplied by the weight of the organ); 
(a) LDU  =  No. of parasites/1000 host nuclei; (b) Total 
LDU = LDU × organ weight × 2 × 105 [32, 40, 41].
Ethical clearance
All procedures were per the Kenya Medical Research 
Institute (KEMRI) operational and approved protocols 
under the bioprospecting for plant based anti-leishma-
nial compounds programme/theme as regulated by the 
Scientific Steering Committee (SSC), Ethical Review 
Committee (ERC) and Animal Care and Use committee 
(ACUC). The guidelines were strictly adhered to during 
the research.
Statistical analysis
The data collected on lesion sizes, parasite loads and 
absorbance were analyzed using the SPSS software. All 
experiments were performed in triplicate, the mean 
standard deviation of at least three experiments were 
determined, statistical analysis of the differences between 
mean values obtained for the experimental groups was 
done by the students t test. P values of 0.05 or less were 
considered to be significant. To determine the efficacy 
range of the chemical dosages used, a logistical model 
which can be used to identify non-linear response to 
ranges of concentrations was fitted to the data. The logit 
model: logit[θ (x)] = Log[θ(x)/1 − θ(x)] = β0 + β1x1 + β
2x2 +…βixi is a general logistic model which takes the 
form log[ρ/1 − ρ] = β0 + β1C + β2C2 + β3 + C3 in dose 
response treatments [42]; where ρ denotes the probabil-
ity of survival, β0 is an intercept, β1 is the coefficient of 
concentration C, and β2 is the coefficient of quadratic 
response in C while β3 is the coefficient of cubic response 
in C. All analyzed results were declared significant at 
p < 0.05.
Results
Results indicating the cell viability of the Vero-E6 cells 
subjected to the test drugs are shown in Fig. 1. The Vero-
E6 cells were significantly affected by treatment using the 
test drugs of A. indica, R. communis and A. indica + R. 
communis (p < 0.05). The concentration of the test drug 
required to destroy 50 % of the mammalian cell was sig-
nificantly low in R. communis (92 µg/mL) followed by A. 
indica + R. communis (101 µg/mL) and highest in treat-
ment using A. indica (149 µg/mL).
The promastigotes growth was significantly affected 
by the various plant extracts (p  <  0.05) after exposure. 
The % growth inhibition estimated for the promastig-
ote form of parasite fully fitted the logistic regression 
model (Table  1). Based on the model parameter coef-
ficients of C, the most effective drug against promastig-
otes was Amphotericin B followed by Pentostam which 
are standard drugs for leishmaniasis. Among the extracts 
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the combined therapy of A. indica and R. communis was 
found to be the most effective drugs followed by A. indica 
while R. communis was the least effective. The efficacy of 
different concentrations of R. communis, A. indica, A. 
indica + R. communis and standard drugs Pentostam and 
Amphotericin B on promastigotes of L. major is shown 
in Fig.  2. The optimal efficacy, concentration at optimal 
efficacy, IC90, IC50 of the extracts and standard drugs 
against promastigote forms of the parasite are shown in 
Table 2. There were significant differences in the optimal 
efficacy of the test drugs (p < 0.05). The optimal efficacy 
of the standard drugs was 98 and 96.5 % for amphotericin 
B and Pentostam respectively. Among the test extracts, 
combined therapy of A. indica and R. communis was the 
most effective against promastigote followed by A. indica 
while R. communis was the least effective. There was sig-
nificant (p < 0.05) differences in the IC50 with the lowest 
IC50 occurring in A. indica + R. communis, followed by 
A. indica and least in R. communis among the known 
standard test drugs.
The efficacy of different concentrations of plant 
extracts and standard drugs, on amastigotes of L. major 
is presented in Fig. 3. The amastigote growth was signifi-
cantly affected by the various test plant extracts (p < 0.05) 
of exposure. The % growth inhibition estimated for the 
amastigote form of parasite fully fitted the logistic regres-
sion model (Table 3). Based on the model parameter coef-
ficients of C, the most effective drug was amphotericin 
B followed by Pentostam, which were standard drugs. 
Among the test drugs that were used in the current study, 
the combined therapy of A. indica +  R. communis was 
found to be the most effective drugs followed by A. indica 
then R. communis. The optimal efficacy, concentration at 
optimal efficacy, IC90, IC50 of the test drugs against amas-
tigote forms of the parasites are described in Table 4. The 
optimal efficacy of the extracts was 72, 59.5 and 88 % A. 
indica, R. communis and combination of A. indica and 
R. communis respectively, compared to standard drugs 
that had 98 and 92  % for Pentostam and amphotericin 
B respectively. Only combined therapy of A. indica + R. 
communis (34.5  µg/mL) achieved IC90 compared to the 
test drugs which had 15.5 µg/ml, 24.5 µg/ml, for Pento-
stam and ampotericin B respectively. There was signifi-
cant (p < 0.05) difference in the IC50 with the lowest IC50 
occuring in A. indica  +  R. communis, followed by A. 
indica and least in R. communis among the known stand-
ard test drugs.
The nitric oxide production in macrophages of BALB/c 
mice infected with L. major amastigotes and subjected 




























Fig. 1 Cell viability of the Vero‑E6 cells subjected to the test extracts
Table 1 Model parameter statistics from the logistic regression of the five test extracts against promastigotes of L. major
Az + Rc, combination of R. communis and A. indica; AMB, amphotericin B
Test drug Model Parameter significance
A. indica Log (ρ/1 − ρ) = 0.434 + 0.384 × C − 0.0008 × C2 + 0.0001 × C3 β0(0.0000) β1(0.0000) β2(0.0001) β3(0.0026)
R. communis Log (ρ/1 − ρ) = 0.225 + 0.324 × C − 0.0008 × C2 + 0.0008 × C3 β0(0.0000) β1(0.0000) β2(0.0002) β3(0.0123)
Az + Rc Log (ρ/1 − ρ) = 0.125 + 0.454 × C − 0.0008 × C2 + 0.0011 × C3 β0(0.0000) β1(0.0000) β2(0.0003) β3(0.0016)
AMB Log (ρ/1 − ρ) = 0.015 + 0.684 × C − 0.0008 × C2 + 0.0004 × C3 β0(0.0000) β1(0.0000) β2(0.0004) β3(0.0021)

































Fig. 2 Promastigote growth inhibition following treatments with 
various test extracts
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Nitric Oxide decreased in the order R. communis  >  A. 
indica + R. communis > A. indica, hence treatment with 
combination therapy leads to more production of NO 
by the macrophages than that from standard drugs and 
monotherapy of A. indica. The Nitric Oxide produced by 
macrophages treated with Pentostam and Amphotericin 
B were the lowest during the experiment. Infected mac-
rophages treated with RPMI produced high amounts of 
nitric oxide.
The lesion sizes of BALB/c mice at the start of infec-
tion, during and the start of treatment with plant 
extracts and controls is shown in Fig.  5. There were no 
significant differences in development of lesion sizes in 
BALB/c mice during the first 5 weeks post-infection with 
L. major (p  >  0.05). Differences in lesion sizes between 
weeks 5 to week 10 were subjected to repeated measure 
ANOVA, which indicated that there were significant 
differences in lesion sizes among different treatments 
(F  =  df  =  p  =  0.05). The lesion sizes of the untreated 
controls of BALB/c mice increased steadily after infec-
tion. Smallest lesion sizes occurred in BALB/c mice 
treated with combination therapy and amphotericin B, 
which was slightly lower than BALB/c mice, treated Pen-
tostam. BALB/c mice treated with monotherapies of A. 
indica or R. communis had larger lesion sizes. Treatment 
of BALB/c mice with R. communis resulted in the least 
reduction in lesion sizes among all the tested drugs post 
treatment. There was no significant difference between 
the combined therapy and Pentostam (p > 0.05); however 
the monotherapies showed lower activity than standard 
drugs.
Body weights, weight of spleen, spleen-somatic index 
and number of parasites in BALB/c infected with L. major 
under various treatments is shown in Table 5. There were 
significant differences in the weight of spleen, spleno-
somatic index and number of parasites among treat-
ments (p < 0.05). In L. major infected BALB/c mice, the 
spleen and spleno-somatic index was found to be signifi-
cantly high when treatment was done using R. communis 
followed by A. indica. There was no significant difference 
between that of combination therapy of A. indica +  R. 
communis and Pentostam. The index was highest in the 
untreated controls. BALB/c mice treated with Pentostam 
and those treated with Amphotericin B, the differences in 
spleen weight were not significant (p > 0.05). The num-
ber of parasites was also high in untreated controls, fol-
lowed by those treated with R. communis and A. indica 
while combination treatment with A. indica  +  R. com-
munis was lower. Nevertheless, treatment using ampho-
tericin B and Pentostam resulted in the lowest numbers 
of parasites.
There were significant differences in the LDU of L. 
major parasites in BALB/c mice treated with monothera-
pies of A. indica, R. communis and a combination of A. 
indica + R. communis (ANOVA; F = df = P = 0.05). In 
L. major infected BALB/c mice, treatment with Pentos-
tam, amphotericin B and combination therapy resulted 
in the lowest LDU. The LDU decreased in order of: R. 
communis > A. indica > A. indica + R. communis. There 
were no significant differences between LDU of BALB/c 
mice treated with Pentostam and that treated with 
Table 2 Optimal efficacy, IC90 and IC50 of test extracts against promastigote form of the parasite
Az, A.indica; Rc, R. communis; Az + Rc, combination of A. indica and R. communis; AMB, amphotericin B
Concentration (µg/mL) Test drugs Controls Parameter and  
statistics
Az Rc Az + Rc Pentostam AMB F value P value
Optimal efficacy (%) 78 61.5 91.2 96.5 98 26.654 0.002
Concentration at optimal efficacy 43.5 69.5 55.2 30.4 40.2 9.257 0.012
IC90 – – 42 16.2 25.1 15.226 0.003
IC50 10.1 25.5 12.2 4.1 5.0 15.456 0.000
Fig. 3 Amastigote growth inhibition following treatments with the 
test extracts
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combination therapy (p  <  0.05). The LDU of L. major 
parasite in BALB/c mice infected with L. major receiving 
various treatments is shown in Fig. 6.
Discussion
Chemotherapy against leishmaniasis is mainly based on 
the antimonial compounds, sodium stibogluconate and 
meglumine antimoniate (glucantine). The mode of action 
of antimonials is poorly understood, and -their toxicity 
causes serious side effects that often result in patients 
deserting treatment. Furthermore, there is a worldwide 
escalating frequency of chemo-resistance to antimonials, 
thus, affordable alternative drugs against leishmaniasis 
are momentously needed. This study set out to determine 
the antileishmanial activities of A. indica and R. com-
munis used in combination and independently against 
L. major infection in susceptible BALB/c mice. A com-
bination therapy of A. indica and R. communis was very 
efficient in decreasing lesions in infected BALB/c mice. 
This antileishmanial activity was compared to that of the 
standard drugs. The combination therapy was also highly 
cytotoxic to the promastigotes and amastigotes in  vitro 
while nontoxic to the macrophages and the VeroE6 cells. 
In vivo, basing on the behaviour of the mice, the extracts 
were well tolerated during the treatment period.
The monotherapies were initially tested for their 
antileishmanial activity and the results of this study 
showed that A. indica was of higher potency than R. 
communis however their cytotoxicity against peritoneal 
macrophages as well as veroE6 cells was still lower than 
that of the standard drugs. The methanolic extract of R. 
communis reduced L. major lesion development, as well 
Table 3 Model parameter statistics from the logistic regression of the plants extracts against amastigote of L. major
Az + Rc, Combination of R. communis and A. indica; AMB, amphotericin B
Test drug Model Parameter significance
A. indica Log (ρ/1 − ρ) = 0.434 + 0.384 × C − 0.0008 × C2 + 0.0001 × C3 β0(0.0000) β1(0.0000) β2(0.0001) β3(0.0026)
R. communis Log (ρ/1 − ρ) = 0.225 + 0.324 × C − 0.0008 × C2 + 0.0008 × C3 β0(0.0000) β1(0.0000) β2(0.0002) β3(0.0123)
Az + Rc Log (ρ/1 − ρ) = 0.125 + 0.454 × C − 0.0008 × C2 + 0.0011 × C3 β0(0.0000) β1(0.0000) β2(0.0003) β3(0.0016)
AMB Log (ρ/1 − ρ) = 0.015 + 0.684 × C − 0.0008 × C2 + 0.0004 × C3 β0(0.0000) β1(0.0000) β2(0.0004) β3(0.0021)
Pentostam Log (ρ/1 − ρ) = 0.012 + 0.724 × C − 0.0008 × C2 + 0.0014 × C3 β0(0.0000) β1(0.0000) β2(0.0001) β3(0.0089)
Table 4 Optimal efficacy, IC90 and IC50 of test extracts against amastigote form of the parasite
Az, A. indica; Rc: R. communis; Az + Rc combination of A. indica and R. communis; Pento, pentostam; AMB, amphotericin B
Concentration (µg/mL) Test drugs Parameter and statistics
Az Rc Az + Rc Pento AMB F value p value
Optimal efficacy (%) 72 59.5 88 98 92 17.311 0.002
Concentration at optimal efficacy 25.5 28.2 35.1 25.2 34.5 9.212 0.001
IC90 – – 34.5 15.5 24.5 19.221 0.001






































Fig. 4 Nitric oxide production in the macrophages of BALB/c 
infected mice infected with L. major and subjected to different treat‑































Fig. 5 Effect of mono and combination therapy on L. majorlesion 
development in BALB/c mice
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as parasite loads in the spleen; this suggests the extract 
was successful in inhibiting L. major parasite growth. 
Though the activity was lower than that of the standard 
drugs, this may be attributed to the fact that the extracts 
in this study were used in their crude form. Studies 
have shown that isolation of active ingredients of plant 
extracts improves their potency [43]. If the bioactive phy-
tochemical compounds of R. communis that are targeted 
at L. major are isolated while eliminating those that are 
cytotoxic to body cells it may give different results. This 
current study is consistent with earlier studies [35, 44] 
that show potential antimicrobial effect of R. communis 
with evidence of in vivo and in vitro activities of the plant 
extracts.
Treatment with A. indica extracts also exhibited 
marked reduction in lesion development and parasite 
load in vitro and in vivo. It is more active against promas-
tigotes than amastigotes but causes production of very 
low levels of NO from macrophages than that produced 
by other test compounds. This indicates its low induc-
tion activity on peritoneal macrophages for production 
of NO, than that observed in R. communis treatment. Its 
activity is however better than the standard drugs in term 
of their cytotoxicity to the macrophages and veroE6 cells. 
It also fits the logistic regression model for drug adminis-
tration; which shows its high potential as a candidate for 
treatment of the L. major infection [42]. These findings 
agree with earlier studies using the same extracts against 
parasitic organisms of trypanosomatidae [43, 45] and 
recent work on L. donovani [16].
The significant decrease in the lesion sizes in the com-
bined therapy is indicative of the occurrence of a syner-
gistic mechanism between the drug combinations. The 
two extracts have different modes of action and their 
combination tends to improve their antileishmanial 
activity. Moreover, the progression of the splenomeg-
ally and the increase of the splenic load were found to 
be significantly lower in treated mice than in untreated 
controls, demonstrating parasite suppression and the 
inhibition of parasite growth. The spleen is a major site 
of Leishmania multiplication in the natural infection in 
susceptible hosts. In BALB/c mice, the splenic parasite 
burden is initially quite low, but it increases steadily for 
at least 3 months, and unlike the hepatic burden, it does 
not decline spontaneously without treatment [6]. The 
splenic efficacy of the test compounds should be empha-
sized, since until recently splenectomy was performed 
as the last recourse for cases of antimony resistant leish-
maniasis. It is evident from the monotherapy results that 
treatment with either A. indica or R communis resulted 
in parasite inhibition but at a lower level than for com-
bination therapy. It can therefore be concluded that 
Table 5 Body weight, weight of spleen, spleno-somatic index and number of parasites in BALB/c mice following various 
treatments
Means in the same column followed by the same superscript show no significant difference between them
Az, A. indica; Rc, R. communis; Az + Rc, A. indica and R. communis (combination therapy); PBS, phosphate buffered saline (negative control); Pentostam, standard drug 
(positive control); Amphotericin B, standard drug (positive control)
Treatment Body weight Weight of spleen Spleno‑somatic index No of parasites
Az 22.11 ± 0.54 0.18 ± 0.021c 0.84 ± 0.10c 37.3 ± 6.4c
Rc 21.78 ± 0.89 0.23 ± 0.021b 1.04 ± 0.08b 58.4 ± 9.8b
Az + Rc 20.50 ± 0.45 0.15 ± 0.006a 0.73 ± 0.02a 26.4 ± 0.7a
Amphotericin B 21.00 ± 1.00 0.13 ± 0.005a 0.74 ± 0.06a 25.7 ± 0.5a
Pentostam 21.00 ± 0.58 0.14 ± 0.010a 0.75 ± 0.07a 26.1 ± 0.4a
PBS 21.00 ± 1.73 0.37 ± 0.014d 1.83 ± 0.21d 145.7 ± 6.7d
ANOVA
 F 2.1332 35.255 71.214 46.987
 df 5 5 5 5






























Fig. 6 The LDU of L. major parasite in spleen of BALB/c mice infected 
with L. major receiving various treatments
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administration of the combination of drugs is effective 
and superior to individual drugs. The synergism shown 
with the combined drugs brings us to the concept of 
structure–function approach in fighting leishmaniasis. 
The effect of combination therapy of A. Indica and R. 
communis may be due to complementarity between the 
two extracts. The standard drugs are known to exhibit 
cytotoxicity to the cells and cause inflammation at the 
site of infusion Combination therapy also leads to pro-
duction of more NO by the macrophages than is seen 
in the monotherapy of A. Indica, thus suggests that the 
latter treatment up-regulates production of NO by the 
macrophages and this may be one of the ways in which 
the parasites are eliminated from the macrophages, Con-
sidering that the efficacy towards promastigotes is higher 
than that against amastigotes, the combined therapy may 
also have direct cytotoxicity toward the parasites. The 
penetration of the test compounds into macrophages is 
hence comparable to that of amphotericin B and poorer 
than that of Pentostam. Pentostam has been reported 
to have better action against amastigotes due to its high 
penetration ability into the macrophages. However, the 
efficacy of the combination therapy may still be low com-
pared to the standard drugs except for good LDU data, 
because the extracts were used in their crude form. Using 
a combination therapy and administration through intra-
peritoneal route therefore may have the potential as a 
good intervention to treatment of cutaneous leishmania-
sis in murine models.
Macrophages, the target cells in therapy of leishma-
niasis play an important role in the immunological con-
trol of intracellular parasites through the production of 
cytokines and oxygen metabolites [46]. One of the main 
mechanisms is the up-regulation of nitric oxide inside 
the macrophages, which is an effective mediator in kill-
ing amastigotes [47]. In this study combination therapy 
caused a slight increase in the NO produced by the mac-
rophages, a slight improvement from that produced by 
the monotherapies which suggests that it may be one 
of the modes of action of the extracts but not the only 
mechanism involved in parasite elimination. This is not 
seen among the standard drugs. However it is consist-
ent with previous studies that R. communis up-regulates 
production of NO, though in small quantity in the mac-
rophages. A. indica may have other mechanism by which 
it causes its anti-parasitic activity apart from just increas-
ing the amount of NO. This study is in tandem with pre-
vious studies that dispute the fact that A. indica is capable 
of activating the immune system to induce production of 
interferon-gamma (IFN-γ) and tumor necrosis factor-
alpha (TNF-α) [48], cytokines that act in synergy in the 
activation of macrophages to produce nitric oxide and 
control the infection by Leishmania [49]. It is however 
in agreement with the fact that A. indica does not cause 
up-regulation of NO in the macrophages [43]. The com-
bined therapy however, has a synergy of action leading to 
its activity, which causes immunomodulatory action. This 
may have been a point where synergism is well demon-
strated by the combined therapy.
The effect of the drugs on the VeroE6 cells in  vitro 
shows that the toxicity of the two extracts is still in the 
manageable range, this also improves in combination. 
This was also observed in the in  vivo experiments for 
none of the mice died during the experimental period 
and there was no marked weight reduction or ill health 
among the treated mice. This may be due to the fact that 
for R. communis, the leaves are less toxic, have lesser 
ricin, than the fruits which has been documented to be 
very toxic [43, 50, 51]. A. indica too was only cytotoxic 
to the parasites but less toxic to the veroE6 cells and the 
macrophages. The extracts studied showed excellent 
antileishmanial activity that was unrelated to toxicity, 
which guarantees safety to the macrophages and speci-
ficity to the parasite which is consistent with studies by 
Nwaka and Hudson [52]. Combining the two drugs does 
not seem to increase toxicity to veroE6 cells and perito-
neal macrophages but improves their potency against the 
amastigotes and promastigotes. This gives a good base 
for further investigation to access whether these extracts 
could become valid candidates for drug development.
There are some limitations associated with this study. 
First, the in vivo treatment majorly focused on intraperi-
toneal mode of administration hence other modes of 
treatment that is intravenous and subcutaneous should 
also be explored. To confirm on the non-toxic nature of 
the plant extracts, the effect that various factors such as 
the growth stage and maturity of the plant, regional vari-
ations (where the plant is growing) should be looked into. 
Leishmaniasis associated cytokine profiles (interferon-
gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α 
among others) were not analyzed. The evaluation can 
help give more insight on the synergistic effect of the 
extracts.
Conclusion
Results from this study indicates that both plant 
extracts have antileishmanial activity. The two medici-
nal extracts when used in combination have syner-
gistic effects in treatment of leishmaniasis. Results of 
this study also indicated that the test plant extracts 
had relatively higher cytotoxicity to parasites than the 
host cells at concentrations used to inhibit growth of 
the parasites. Based on the observed antileishmanial 
activity and low or absence of cytotoxicity on the host 
cells, it is suggested that a combination therapy of R. 
communis and A. indica be used for bioassay-guided 
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fractionation, isolation of bioactive compounds and 
their fortification, which could serve as new drug lead 
structures. Isolation of bioactive components can also 
be carried out with the intention of removal of compo-
nents with strong cytotoxic effects as well as identify 
and mark those active compounds for antileishmanial 
activity.
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